Currently, ongoing pharmacotherapy trials for NAFLD and NASH focus on a multitude of mechanisms and diverse targets, including insulin resistance, de novo lipogenesis, oxidative stress, targeting nuclear receptor, and immune or inflammatory signaling. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.